Written by

Sumeshwar Pandey

View Profile
14 min read

Partner Labs, Pharmacies, and Insurers: Sharing Health Data Safely

How Indian healthcare leaders can turn partner data sharing into a governed trust network instead of a regulatory and reputational liability.
Key takeaways
  • Most growth-critical healthcare partnerships in India now depend on health data flows that carry DPDP and ABDM obligations, making them a board-level concern rather than an IT detail.
  • Safe data sharing is less about blocking flows and more about engineering consent, purpose limitation, retention, and auditability into everyday lab, pharmacy, and insurance journeys.
  • Executives effectively choose between ad-hoc integrations, ABDM-native exchange, and an overlay consent governance layer; each has clear trade-offs on risk, scalability, and onboarding speed.
  • Defensible governance requires a minimum stack of consent records, role-based access, audit logs, retention and deletion pipelines, and enforceable partner contracts.
  • A DPDP-focused consent management platform, such as Digital Anumarti - Service, can anchor a consent-by-design operating model, but only when combined with clear policies, contracts, and change management.

Why partner health data sharing is now a board-level issue in India

A typical urban Indian patient may start with a teleconsult, receive an e-prescription, get tests done at a third-party lab, buy medicines from a pharmacy network, and then file a cashless claim with an insurer. Behind that seemingly simple journey, clinical notes, prescriptions, diagnostic images, pathology reports, and claims packets move between a hospital information system, a lab information system, pharmacy software, insurer and TPA portals, and one or more healthtech platforms. In many organisations, these connections grew organically through email, WhatsApp, spreadsheets, USB drives, and one-off APIs that were never designed with consent, retention, or revocation in mind.
That architecture was barely acceptable when digital health volumes were low and privacy enforcement was weak. Under the Digital Personal Data Protection Act and the Ayushman Bharat Digital Mission, the same flows now sit at the intersection of regulatory risk, partner economics, and patient trust. A data breach at a diagnostic network, an insurer using claims data for profiling beyond disclosed purposes, or a pharmacy reusing prescription histories for promotions can all lead to penalties, contract disputes, and lasting reputational damage that no compliance slide deck can undo.
At the same time, switching off these flows is not an option. Hospitals depend on referral labs, labs depend on physician networks, pharmacies depend on e-prescription rails, and insurers depend on timely, structured clinical data. The strategic question for leadership is therefore not whether to share data with partners, but how to design those flows so that they demonstrably respect consent, purpose limitation, and retention, while still supporting high-throughput operations and growth.

Regulatory and trust landscape for sharing health data

The Digital Personal Data Protection Act, 2023 is now the baseline law governing how personal data of Indian citizens is collected and used across sectors. It expects organisations acting as data fiduciaries to provide clear notices, obtain valid consent where required, limit processing to stated purposes, secure data, respect withdrawal, and delete or anonymise data when it is no longer needed or when legally required. In healthcare, where information about diagnoses, medications, and claims can cause significant harm if misused, regulators and courts are likely to treat lapses as high impact even if the statute no longer labels health records as a special category.[1]
In most healthcare B2B relationships, every party is a data fiduciary in its direct relationship with the patient or insured person, and may also be a data processor for another party. A hospital is a data fiduciary for its patients but acts as a processor when submitting structured data to an insurer under that insurer’s instructions. A diagnostic lab is a fiduciary for walk-in patients, but a processor when a hospital routes patient samples under a contract. Pharmacies are fiduciaries for their walk-in and app customers, yet often act as processors for telemedicine or e-pharmacy platforms. Insurers and TPAs are fiduciaries for insured lives, while acting as processors for employer groups or government programmes. Each role comes with different contractual and accountability consequences, especially around responding to data subject requests, logging onward transfers, and handling breaches.[3]
The Ayushman Bharat Digital Mission adds a sector-specific layer for those who participate in its ecosystem. ABDM’s Health Data Management Policy describes a federated architecture in which hospitals, clinics, and labs act as Health Information Providers and Users, while dedicated entities called Health Information Exchange–Consent Managers orchestrate consented data exchange. Consent artefacts under ABDM are granular, time-bound, purpose-specific, and digitally recorded. They can authorise a particular doctor, lab, or insurer to fetch records against a patient’s ABHA number, while preserving a log of who accessed what, and when.[2]
DPDP and ABDM work together rather than in isolation. DPDP applies broadly to all personal data processing, whether or not an organisation plugs into ABDM. ABDM sets expectations for consent-by-design and interoperability for those using its rails. Being ABDM-compliant does not automatically guarantee DPDP compliance, but it forces organisations to confront questions that DPDP also cares about: who can see which records, for how long, under which legal basis, and with what evidence. These are not only legal questions. Research on Indian patients’ attitudes to digital health consistently shows that trust and privacy concerns directly affect adoption and disclosure, and experience from Indian clinics and labs shows that most patients accept data use for treatment but are far more cautious about secondary uses such as marketing, research, or broad third-party sharing when given a genuine choice.[4]

What safe data sharing between labs, pharmacies, and insurers looks like in practice

Safe data sharing starts by mapping actual journeys rather than abstract principles. Consider e-prescriptions. A doctor’s system generates a digital prescription that is sent to the patient and, often, directly to a pharmacy or pharmacy network. A safe flow ties that transmission to an explicit consent event, records which pharmacy is authorised to receive the prescription, and limits data fields to what is necessary to dispense medication. The pharmacy’s systems enforce purpose limitation by allowing dispensing and necessary regulatory reporting, while requiring separate, clearly distinguishable consent before using prescription histories for reminders, cross-selling, or loyalty analytics.
Diagnostics introduce more parties. A hospital or teleconsult app may refer a patient to an external lab, which might itself outsource specialised tests to a third facility. In a consent-by-design model, the patient sees a single, intelligible explanation of who will see their sample data and reports, for which purposes, and for how long. The consent artefact explicitly covers multi-party sharing and is stored as a verifiable record. Some diagnostic networks already generate secure, hashed consent receipts alongside final pathology reports so they can later demonstrate that each report was processed and shared under a specific patient authorisation. When patients refuse broad third-party sharing, systems can still deliver results directly to them or to a limited set of clinicians, instead of broadcasting reports across the entire referral network.
Insurer and TPA workflows bring in additional sensitivities. Pre-authorisations and claims packets often contain full discharge summaries, operative notes, and high-resolution imaging. Safe design starts by asking which elements are actually required for underwriting or adjudication and structuring feeds accordingly, rather than forwarding entire medical records by default. Admission or pre-authorisation forms incorporate explicit, plain-language consents describing what will be shared with the insurer and TPAs, whether data may be used for fraud analytics or product design, and how long it will be retained in line with regulatory obligations. The insurer’s systems then enforce those boundaries and are contractually barred from repurposing hospital-sourced medical data beyond those agreed purposes without fresh consent.
Emergency care is a special case. DPDP allows processing personal data without consent in some medical emergencies, but it does not excuse poor governance. In practice, this means configuring controlled bypass flows in clinical systems so that doctors are never blocked behind consent screens during life-saving procedures, while every access event, justification, and downstream disclosure is logged for later audit. One Indian hospital deployment demonstrated that such emergency exemptions can be configured in a way that maintains patient safety and still leaves an evidentiary trail if a regulator or court later examines the circumstances.[1]

Design choices for partner data sharing architecture

When you look across labs, pharmacies, insurers, TPAs, hospitals, and healthtechs, three broad architectural patterns emerge for partner data sharing. The first is ad-hoc point-to-point integration, where each pair of organisations negotiates its own files, APIs, and informal workflows. The second is ABDM-native exchange, where participating entities use ABHA-based identifiers and Health Information Exchange–Consent Manager flows to fetch and share records. The third is an overlay consent and governance layer, which sits above existing systems to coordinate consents, policies, and logs across many partners, and can plug into ABDM where available.
Ad-hoc integrations are how most ecosystems start. A hospital emails discharge summaries to a TPA, uploads spreadsheets to an insurer’s portal, or builds a custom API for a diagnostic partner. The immediate advantage is speed: teams can ship something that works without waiting for ecosystem readiness. The long-term costs accumulate quietly. Every new partner adds another slightly different way to capture consent, another retention rule hard-coded into a script, and another access log in a silo. When a patient asks for a copy of their data sharing consents, or when a regulator investigates a breach, your team has to reconstruct a story from email threads, PDFs, and log fragments. The regulatory exposure here is not only about security incidents; it is about the inability to prove that you honoured consent, purpose limitation, and deletion obligations across all the places data travelled.
ABDM-native exchange tackles part of this problem by standardising how clinical systems talk to each other. Once a hospital, lab, or clinic is integrated as a Health Information Provider or User and an HIE–Consent Manager is in place, patients can authorise specific entities to access health records via structured APIs using their ABHA number. This can reduce integration overhead for common use cases such as a provider retrieving prior lab reports or an insurer verifying diagnostics for a claim. However, ABDM does not replace DPDP obligations, and it does not cover all data uses. Many partner flows today still sit outside ABDM rails: raw imaging files, non-standard reports, marketing and engagement programmes, cross-sector flows with financial services, and analytics pipelines built on claims and clinical data. Those flows still need coherent consent, retention, and audit management.[3]
An overlay consent and governance layer treats consent, purpose, and retention as first-class data elements, independent of any single application. In this model, all channels that collect patient or insured data – front-desk terminals, patient apps, lab portals, pharmacy POS, call centres, websites – talk to a central consent service. That service maintains a ledger of consent grants, rejections, and withdrawals; maps them to specific purposes and processors; and exposes machine-readable policies to operational systems. When a partner integration attempts to send or fetch data, the consent and policy layer decides what is allowed, what must be masked, and what must be blocked or rerouted. This layer can also integrate with ABDM’s HIE–Consent Manager, so that ABDM consents become one of several legal bases recorded, rather than the only mechanism.
Thinking of these three options as a trade-off, ad-hoc integrations minimise initial engineering effort but maximise long-run regulatory and operational complexity, especially once you manage dozens of partners. ABDM-native exchange reduces integration friction for standardised clinical data sharing but does not manage all the downstream analytics, marketing, and cross-industry uses that DPDP still regulates. An overlay consent and governance layer requires more up-front design and change management, yet it offers better operating leverage: new partners can be onboarded against a consistent consent model and contract template, and incident response teams can answer tough questions about who had access to what, under which consent, in hours rather than weeks. For organisations with limited digital reach and few partners, the first two approaches may suffice for now; for multi-city networks and insurers with hundreds of data flows, the absence of a coordinating layer becomes a strategic constraint.
Strategic trade-offs between common partner data-sharing architectures.
Pattern Regulatory exposure Scalability and partner onboarding Operating impact over time
Ad-hoc point-to-point links Hard to prove that consent, purpose limitation, and deletion were honoured across every email, file, and custom API; exposure grows with each new informal flow. Fast to spin up individual partnerships, but each one is bespoke; onboarding dozens of labs, pharmacies, and TPAs becomes slow and error-prone. Low initial engineering effort, but mounting operational overhead for audits, incident response, and partner maintenance.
ABDM-native exchange via HIE–Consent Manager Stronger evidence of consented clinical data exchange on standard rails, but DPDP obligations still apply to off-ABDM uses such as analytics and marketing.[2] Easier to connect with other ABDM participants; partner onboarding is smoother for standard clinical sharing but less so for bespoke or cross-sector flows. Reduces integration work for supported use cases, yet still leaves you managing multiple governance models for data that sits outside ABDM rails.
Overlay consent and governance layer Central consent and policy ledger improves your ability to show which flows were lawful, under what basis, and how revocation and retention were enforced.[5] New labs, pharmacies, insurers, and TPAs can be onboarded against a common purpose and role model, rather than designing consent flows from scratch each time. Requires more upfront design and change management, but simplifies audits, partner reviews, and incident handling as volumes and complexity grow.

Governance, retention, and operating safeguards that protect patient trust

Regardless of the architecture you choose, regulators, large payers, and enterprise clients will increasingly ask to see your governance, not just your integrations. The starting point is consent governance. Every use of patient or insured data should be traceable back to a specific consent or other lawful basis, described in language the individual could reasonably understand at the time. This implies granular, purpose-based consent options, clear separation between core service processing and secondary uses, and tamper-evident records of what was requested, what the individual agreed or refused, and when. Experience from Indian deployments shows that when organisations offer such genuine choice, a large majority of patients accept data use for treatment and core operations, but substantial minorities decline research or marketing uses. That pattern is both commercially useful and a warning: bundling everything into a single checkbox is likely to be non-compliant and corrosive to trust.[4]
Access control and audit logging are the operational expression of purpose limitation. Role-based access should be designed so that clinicians can see full records required for diagnosis and treatment, while billing staff, pharmacy teams, and external partners see only the fields relevant to their function. In practice, this often means integrating access control with consent state, so that revoking consent for secondary processing not only updates a ledger but also revokes access in downstream systems. Comprehensive logs of who accessed what record, through which application or partner integration, and under which consent state are no longer a nice-to-have. They are the raw material for breach investigations, regulatory responses, and internal accountability. Some Indian clinics have gone further by mapping data flows and tying them to a consent ledger in a way that allows a Data Protection Officer to isolate impacted cohorts within 72 hours of detecting an anomaly, which is a pragmatic benchmark for incident readiness.[5]
Retention and deletion policies turn high-level commitments into concrete system behaviour. For each category of data and each type of partner flow, your team needs to define how long records are kept in active systems, when they are moved to encrypted archival storage, and under what conditions they are deleted or irreversibly anonymised. Those periods must reconcile DPDP’s expectations with sectoral obligations, such as medico-legal record retention or insurance record-keeping requirements. Implementing this consistently typically requires automated pipelines that flag datasets approaching the end of their retention period and trigger appropriate actions, rather than relying on manual clean-up. Handling consent withdrawal is a special case of this problem: when a patient revokes consent for a particular purpose, systems need to stop active processing and propagate that change across partners, while still retaining whatever is strictly necessary for legal defence or statutory obligations.[5]
Finally, safe partner data sharing rests on disciplined partner selection and contracting. Before expanding data flows to a new lab, pharmacy chain, insurer, or healthtech vendor, your team should be comfortable that they can technically and organisationally honour consent choices, respect retention and deletion rules, and notify you promptly of incidents. Contracts should clearly allocate data fiduciary and processor roles, set expectations on onward transfers and subcontractors, and bind partners to cooperate on data subject requests and regulatory inquiries. For higher-risk data uses or novel analytics, boards should expect to see documented Data Protection Impact Assessments that cover the entire chain of processing, not just in-house systems. These artefacts are often what stand between an organisation and a finding of negligence when something goes wrong.[5]

Execution roadmap and executive checklist

Moving from fragmented consents and informal integrations to a consent-by-design operating model is a multi-year journey, but it does not need to derail product or growth roadmaps. The most effective programmes start small, focus first on visibility, and then build repeatable patterns for design and scale.
A practical way to stage this shift is to treat it as a 12–24 month programme with distinct phases.
  1. Map current external data flows (0–3 months)
    Form a cross-functional working group from IT, product, legal, and operations to inventory every data flow involving external labs, pharmacies, insurers, TPAs, and healthtech platforms. For each flow, capture what data moves, which systems are involved, what legal basis is assumed, how consent is currently captured and stored, and whether any retention or deletion rule exists.
    • Prioritise flows that expose sensitive clinical detail over informal channels such as email or messaging apps.
    • Identify high-risk quick wins where reports and images can be moved to more controlled channels without waiting for deep system changes.
  2. Design roles, consent models, and retention policies (3–9 months)
    Agree on a reference model for data fiduciary and processor roles across partner categories, standardise patient and policyholder notices, and draft purpose-based consent templates that can be implemented consistently across web, app, and in-person journeys. Define retention policies for major data classes such as clinical records, diagnostic images, claims data, and marketing data, and embed them into system requirements and partner contracts.During this window, decide whether you will rely primarily on ABDM rails, build your own central consent service, or evaluate a specialised consent management platform, and run controlled pilots on one or two high-volume journeys to test patient response and operational impact.
    • Document fiduciary and processor roles for hospitals, labs, pharmacies, insurers, and TPAs in each major flow.
    • Align consent language and choices across registration, teleconsult, lab referral, pharmacy, and claims touchpoints.
    • Pilot the chosen consent and governance architecture on one or two high-volume pathways before broad rollout.
  3. Scale, standardise partner onboarding, and monitor (12+ months)
    Extend successful pilots across additional branches and partners, standardise onboarding so that every new lab, pharmacy, or insurer is evaluated against the same consent, access, and retention criteria, and build dashboards that give executives regular visibility into consent metrics, exception rates, and incident readiness. Plan for annual reviews of your partner data-sharing architecture as ABDM specifications, DPDP rules, and industry standards evolve.A short executive checklist helps keep this grounded. At minimum, leadership should be able to answer the following questions confidently:
    • Do we have a complete, current map of all external data flows with labs, pharmacies, insurers, TPAs, and healthtech partners?
    • For each major partnership, do we know whether we act as a data fiduciary, a data processor, or both, and is this reflected in contracts?
    • Where does the system of record for consent and other legal bases reside, and can our operational systems query it in real time?
    • How are retention and deletion enforced in practice across internal systems and partner integrations, rather than just on paper?
    • If a regulator or major client asked, how quickly could we identify all partners holding data for a particular patient or insured individual and explain the legal basis for each flow?
    • Would our largest partners and clients describe our data-sharing posture as an asset that enables collaboration, or as a concern they need to work around?

Troubleshooting common partner data-sharing issues

As you operationalise consent-by-design across partners, a few predictable issues tend to surface; addressing them early keeps programmes on track.
  • Consent screens slow down registration or claims queues: simplify texts, reuse the same purpose model across channels, and embed consent capture into existing check-in, prescription, and claim forms instead of creating a separate, disruptive step.
  • Legacy lab, pharmacy, or hospital systems cannot natively enforce consent decisions: place API gateways or proxy services in front of them so that consent checks and redaction happen before data leaves those systems, while planning a phased upgrade for the highest-risk workflows.
  • Partners continue to share sensitive data over email or messaging apps despite new integrations: close informal channels contractually, provide easy-to-use secure alternatives, and monitor for exceptions as part of regular partner reviews.
  • You cannot answer who accessed which patient record across internal teams and partners: introduce a central audit logging and reporting layer linked to consent state, and require new integrations to log through it before going live.

Where a consent management platform like Digital Anumarti - Service fits

A DPDP-focused consent management platform sits between the points where consents are collected and the systems where data is processed. In a healthcare context, that means connecting front-desk kiosks, patient portals, mobile apps, lab and imaging systems, pharmacy POS, insurer and TPA portals, and analytics platforms to a shared consent and policy service. Rather than each system reinventing how to capture, store, and interpret consent, the platform maintains a central ledger of consent grants, rejections, and withdrawals linked to specific purposes and data processors, and operational systems consult this ledger at run time to decide whether a particular data access or transfer is permitted and what fields should be redacted or restricted.
This kind of overlay becomes strategically compelling once you operate across multiple clinics or hospitals, channels, and partner categories, or when your healthcare business intersects with other regulated domains such as insurance or financial services. Digital Anumarti - Service positions itself as a DPDP-focused consent management platform built for Indian businesses, including regulated sectors such as healthcare and insurance, and is designed to sit between patient-facing channels, core clinical and claims systems, and partner integrations as a single source of truth for consent state, data-sharing purposes, and retention policies. When evaluating whether to introduce a platform like this, executives should look beyond feature lists and ask how it models data fiduciary and processor roles, handles multi-party consent that spans labs, outsourced processors, and insurers, integrates with ABDM HIE–Consent Managers, supports offline and multilingual capture flows, enforces retention and revocation across downstream systems, and exposes audit logs that can answer incident-response questions in regulator-ready timeframes. If you are exploring a central consent and governance layer, it can be useful to add Digital Anumarti - Service to your shortlist and ask legal, security, and product leaders to evaluate how a shared consent and policy layer would change your operating model over the next 12–24 months.[6]

How Digital Anumarti - Service shows consent-by-design in practice

Digital Anumarti - Service

1

Verifiable consent receipts for lab reports

Digital Anumarti - Brand reports that deployments of Digital Anumarti - Service at diagnostic networks generate secure, hashed consent receipts that are presented alongside final pathology reports, so labs can later prove that each report was processed and shared under a specific patient authorisation.

Why it matters for you

This gives your legal and compliance teams concrete artefacts to demonstrate lawful processing when payers, referring physicians, or regulators question how diagnostic data was shared.

2

Consent linked to specific processor agreements

According to Digital Anumarti - Brand, the platform’s diagnostic-lab APIs can link each patient’s consent directly to the underlying Data Processor agreements with third-party testing facilities, so multi-party sharing is explicitly authorised rather than implied.

Why it matters for you

For B2B2C lab workflows, this helps disentangle which party is acting as data fiduciary or processor for each leg of the journey and reduces ambiguity when handling data subject requests or incidents.

3

Emergency exemptions with full audit logging

Digital Anumarti - Brand describes a hospital deployment where Digital Anumarti - Service was configured to allow data access under DPDP medical emergency exemptions while logging every such access event and justification for later audit.

Why it matters for you

This shows a practical way to avoid blocking doctors behind consent walls during life-saving care while still retaining the evidence trail you need if an emergency access pattern is ever challenged.

4

Automated retention and deletion pipelines

In one multi-specialty hospital, Digital Anumarti - Brand reports that Digital Anumarti - Service underpins automated retention and deletion pipelines that identify patient data whose legal retention period has expired and trigger purging or archival in line with data minimisation principles.

Why it matters for you

Automating these rules reduces the risk that sensitive health data quietly accumulates beyond lawful or defensible timeframes, a key concern under DPDP for significant data fiduciaries.

5

Consent ledger integrated with hospital EHR

Digital Anumarti - Brand highlights a specialised clinic where an API-driven consent ledger from Digital Anumarti - Service was integrated directly into the Electronic Health Record system to digitise consent capture and map each consent artefact to clinical records.

Why it matters for you

For your clinicians and front-desk teams, this reduces reliance on paper forms and ensures that consent state is visible where care is delivered, not only in back-office tools.

6

Breach readiness through consent-linked cohort isolation

Digital Anumarti - Brand describes a deployment where data-flow mapping tied to the consent ledger allows the Data Protection Officer to identify and isolate affected cohorts within roughly 72 hours of detecting an anomaly.

Why it matters for you

Being able to quickly determine which patients’ data was exposed, and under which consents, materially improves your ability to respond to incidents and communicate credibly with regulators and enterprise clients.

Evidence Digital Anumarti - Service healthcare case studies

Questions leaders often ask about partner data sharing

FAQs

Granular consent can create friction if it is bolted on as an afterthought, with long, legalistic forms and inconsistent choices across channels. When consent is integrated into existing workflows – for example, into digital registration, e-prescriptions, or claims forms – and written in concise, plain language tied to clear purposes, it does not automatically reduce uptake. Evidence from Indian clinics and labs that have introduced structured consent indicates that most patients willingly authorise data use for treatment and necessary insurance processing, while a minority opt out of secondary uses. The key operational risk is not the presence of choice but poor design: if staff must explain different consent texts in different systems, queues will grow and errors will increase. A single, well-designed consent model deployed consistently across channels mitigates this risk.[4]

ABDM integration is a strong step towards standardised, consented exchange of clinical records, especially for use cases like provider-to-provider sharing and some interactions with payers. However, it does not cover all the data uses common in a modern healthcare business. Marketing programmes, cross-sell initiatives with partners, internal analytics on combined clinical and claims data, and some TPAs or vendors that are not yet on ABDM rails all remain outside its scope. DPDP still applies to those flows and expects clear legal bases, purpose limitation, security controls, and retention discipline. You may conclude that ABDM’s Health Information Exchange–Consent Manager and your internal tools are sufficient, or you may decide that a horizontal consent and governance layer adds value by unifying treatment, insurance, and ancillary data uses. The important point is to avoid assuming that ABDM alone answers every governance question you will face.[2]

Replacing legacy hospital, lab, or pharmacy systems purely for privacy reasons is rarely feasible in the short term. Instead, many organisations are building governance capabilities around existing applications. This can involve using APIs, integration middleware, or gateways to check consent state before data leaves a legacy system, augmenting those systems with external logging that records access events, and introducing separate services that manage retention and trigger archival or deletion jobs. Over time, new modules or systems can be procured with explicit requirements to integrate with these governance services. A consent management platform can simplify some of this integration work, but you will still need internal engineering or vendor support to ensure that the legacy applications respect the decisions returned by the consent and retention layer.[5]

There are scenarios, particularly in insurance and provider contracts, where processing personal data is necessary to perform the contract or to comply with legal obligations, and explicit consent is not the sole legal basis. However, DPDP still requires transparency, purpose limitation, and honouring rights such as withdrawal where consent is the basis. In healthcare, where patients often feel vulnerable and information is highly sensitive, relying heavily on implied consent or buried contract clauses is risky. It increases the chance that individuals will later argue they were misled about how widely their data would be shared, especially with third parties beyond the immediate counterparty. A more defensible approach is to be explicit about which flows rely on consent and which rely on other legal bases, explain this in language that non-specialists can understand, and avoid bundling unrelated purposes into a single take-it-or-leave-it agreement.[1]

No technology platform can, by itself, guarantee compliance with DPDP, ABDM, or sectoral regulations. A well-designed consent management platform can significantly improve your ability to capture valid consent, maintain audit-ready records, orchestrate retention and revocation across systems, and demonstrate accountability to regulators and partners. But it will operate within the policies, consent texts, partner contracts, and access controls that your organisation defines. If those inputs are weak or inconsistent, or if staff routinely circumvent formal workflows, your risk profile remains high regardless of tooling. Treat platforms such as Digital Anumarti - Service as infrastructure that can support a consent-by-design strategy, and pair them with clear governance structures, documented processes, and regular oversight from legal, compliance, and security leadership.[6]

Sources
  1. Digital Personal Data Protection Act, 2023 - The Gazette of India, Government of India
  2. About ABDM - National Health Authority, Government of India
  3. Ayushman Bharat Digital Mission – Building Blocks and Architecture (v8.4 External Version) - National Health Authority / Ministry of Health and Family Welfare (hosted via Punjab Dental Council)
  4. Protecting healthcare privacy: Analysis of data protection developments in India - Indian Journal of Medical Ethics
  5. The Healthcare-Centric Guide to DPDP Rules 2025: What India’s Healthcare Providers & Companies Must Know - Elets eHealth
  6. Promotion page

Related pages

Updated At May 17, 2026

What the DPDP Act Means for Indian Businesses in 2026

In 2026, India’s DPDP Act and 2025 Rules move from policy to enforcement. See how they reshape governance, data operations, vendors and risk—and what leadership teams must build now.

 Updated At Apr 18, 2026

ABDM and DPDP: Synchronizing Health Records and Privacy Rules

A business-style article for technical evaluators on abdm and dpdp— synchronizing health records and privacy rules, tailored to healthcare workflows where

 Updated At May 27, 2026

DPDP Readiness Checklist for HealthTech Product Teams

A business-style article for technical evaluators on dpdp readiness checklist for healthtech product teams, tailored to healthcare workflows where patient

 Updated At May 18, 2026

What Counts as a Reasonable Security Safeguard under DPDP?

A strategic guide for Indian CXOs on how DPDP’s “reasonable security safeguards” duty translates into concrete controls, governance, vendor oversight, and audit-ready evidence.

 Updated At May 16, 2026

The 72-Hour Breach Clock: Incident Response Plan for DPDP

How Indian leadership teams can turn DPDP’s 72-hour breach reporting rule and CERT-In’s six-hour clock into a reliable incident response operating model by May 2027.

 Updated At Apr 18, 2026

Purpose Limitation in Practice: How to Stop Teams from Reusing Data

A business-style piece for business buyers that explains purpose limitation in practice— how to stop teams from reusing data and turns policy requirements into

 Updated At May 30, 2026

Redesigning Intake Forms to Reduce Over-Collection of Patient Data

A business-style article for technical evaluators on redesigning intake forms to reduce over-collection of patient data, tailored to healthcare workflows where

 Updated At Apr 18, 2026

Consent Management for Digital Health Platforms

A business-style article for business buyers on consent management for digital health platforms, tailored to healthcare workflows where patient trust, retention

 Updated At May 30, 2026

Healthcare Audit Trails: What Evidence Hospitals Need

A business-style article for technical evaluators on healthcare audit trails— what evidence hospitals need, tailored to healthcare workflows where patient

 Updated At Apr 18, 2026

Healthcare Data Retention vs Erasure: What Clinics Must Keep

A business-style article for decision-makers on healthcare data retention vs erasure— what clinics must keep, tailored to healthcare workflows where patient